It is also therapeutically relevant that, compared with PSA, the HSD17B2/HSD17B3/SHBG/SRD5A1 4-gene signature is capable of differentiating recurrent/nonresponsive from nonrecurrent/responsive PCa (Figure 6). Here, SRD5A1 is linked to posterior cortical atrophy.